



Berkshire West Area Prescribing Committee

Product Name	Modified release prednisolone (Lodotra®)		
Indication under review	The treatment of Rheumatoid Arthritis		
Policy No:	APC 066		
Date of Issue/ Date of reissue:	January 2014/ March 2017		
Review Date:	March 2020		
Policy Statement:	Modified release prednisolone (Lodotra®) is not recommended for the routine treatment of patients with Rheumatoid Arthritis.		
Traffic Light Status	Brown		
Key Points considered:	<ul style="list-style-type: none"> Modified release prednisolone (Lodotra®) does not have significant benefits over immediate release prednisolone. 28 days treatment with 5mg Lodotra® is more than 20 times the cost of uncoated immediate release prednisolone 5mg. This treatment is therefore not considered to be the most cost effective use of scarce NHS resources. This policy has been produced as a guide for GPs. Evidence and information was carefully considered and consulted upon by clinicians who concluded that this treatment is not a cost effective use of scarce NHS resources. There are situations where this policy may not apply to an individual patient due to their clinical exceptionality. This policy statement does not overrule an individual GPs clinical decision making and therefore each GP would be need to make the final decision on whether treatment is a cost-effective use of their CCG budget 		
References:	<ol style="list-style-type: none"> NICE (2009). Rheumatoid Arthritis. National clinical guidelines for management treatment in adults. CG79. February 2009, available online: http://guidance.nice.org.uk/CG79 Electronic medicines compendium http://www.medicines.org.uk Greenhalgh N, South West Medicines Information, Bristol Royal Infirmary. Prednisolone Modified Release Tablets produced for the UKMI service. 		
Date taken to APC:	1 st March 2017		
Date Ratified by MOC on Behalf of the Board:	15 th March 2017		

Berkshire West Area Prescribing Policies serve as a guide to clinicians. This does not overrule the clinical or budgetary responsibility of clinicians when considering treatment for individual patients.

Brown	Green	Amber	Red
These drugs have been reviewed and are not considered a cost effective use of scarce NHS resources	Medicines suitable for routine use. Primary care prescribers take full responsibility for prescribing	Medicines that should be initiated by a specialist and can be continued in primary care under a shared care agreement.	Medicines which should be prescribed by specialists only